Researchers at the Gladstone Institutes have identified a specific protein, Nell2, that causes neurons in the hippocampus to shrink and fire erratically in carriers of the APOE4 gene variant, the strongest known genetic risk factor for late-onset Alzheimer’s disease. The disruption occurs well before any signs of memory loss or the buildup of amyloid plaques. When the team blocked Nell2 in laboratory models, the abnormal electrical activity reversed, pointing to a potential target for early intervention long before cognitive decline begins.
APOE4 rewires hippocampal circuits decades before diagnosis
The central finding is straightforward: APOE4 does not wait for plaques or tangles to start damaging the brain. In humanized knock-in mice engineered to carry either the APOE3 or APOE4 variant, excitatory neurons in the hippocampus were physically smaller and fired at abnormally high rates in the APOE4 group. That hippocampal hyperactivity appeared at young ages, well before any behavioral signs of memory impairment. The pattern suggests that the gene variant shifts the brain’s electrical balance early in life, creating a slow-burning circuit problem that compounds over time.
Human imaging studies reinforce this timeline. PET scans of young adults who carry the APOE4 allele revealed functional differences in brain activity decades before any dementia diagnosis. Separately, fMRI studies in cognitively intact older adults showed that APOE4 carriers displayed altered activation patterns during memory tasks compared with non-carriers. These are not subtle statistical artifacts visible only to specialists. They represent consistent, replicable shifts in how the brain recruits its memory circuits, and they appear in people who pass every standard cognitive test.
A hypothesis worth testing against this evidence is that APOE4 carriers who show elevated resting-state hippocampal connectivity in midlife may also lose inhibitory neurons faster and accumulate amyloid earlier than non-carriers with similar connectivity profiles. If confirmed, that would mean the circuit disruption is not just a marker of risk but a driver of disease progression. No single study has yet tracked Nell2 levels, inhibitory-neuron counts, and amyloid buildup in the same individuals over time, but the existing animal and human data point in the same direction.
Nell2 protein links APOE4 to excitatory imbalance
The mechanistic story centers on Nell2, a protein whose levels rise in neurons carrying the APOE4 variant. That increase causes excitatory neurons to shrink and become hyperactive, tipping the balance between excitation and inhibition in hippocampal circuits. The Gladstone Institutes team showed that targeting Nell2 reversed the abnormal excitability in their APOE4 models, according to their summary of the work, suggesting that dampening Nell2 signaling could restore a healthier firing pattern.
This finding fits into a broader biological framework. A synthesis in Neuron traced how early neuronal APOE4 effects, including hyperexcitability and excitation–inhibition imbalance, connect to later glial responses and neurodegeneration across the Alzheimer’s continuum. The sequence matters: neurons become electrically unstable first, and the inflammatory and degenerative processes that define clinical Alzheimer’s follow. Earlier research in APOE4 mice had already demonstrated that the gene variant can drive circuit-level hyperactivity through inhibitory dysfunction even in the absence of plaques and tangles. Nell2 now provides a plausible molecular explanation for how that inhibitory breakdown begins.
Longitudinal human data from the Baltimore Longitudinal Study of Aging add another layer. That cohort showed resting-state functional brain changes appearing years before cognitive impairment onset, consistent with the idea that circuit-level disruption is an early event rather than a late consequence. The convergence of mouse genetics, human imaging, and long-term cohort tracking builds a case that APOE4’s damage to brain wiring is both real and early, even if the precise molecular steps in people still need to be mapped.
Open questions about Nell2 and the path to prevention
The biggest gap in the evidence is the absence of direct human data on Nell2 itself. No study has yet measured Nell2 protein levels in living APOE4 carriers across different age groups or correlated those levels with the hippocampal hyperactivity seen on fMRI and PET scans. The mouse findings are compelling, but translating them to human brains requires confirming that the same molecular chain operates in people, not just in engineered animal models.
A second unresolved issue is whether Nell2 is the main driver of APOE4-related hyperexcitability or one of several converging pathways. APOE4 affects lipid metabolism, synaptic pruning, and glial responses, any of which could interact with Nell2 signaling. It is possible that Nell2 plays a dominant role early in life, while other mechanisms take over as amyloid and tau pathology accumulate. Disentangling those contributions will require experiments that manipulate Nell2 at different stages of disease in diverse models, including human neurons derived from induced pluripotent stem cells.
There are also safety questions. The Gladstone work shows that lowering Nell2 can normalize firing in APOE4 neurons, but the protein may have essential functions in healthy brains. Completely blocking Nell2 could risk impairing synaptic plasticity, learning, or resilience to stress. Any future therapy would need to modulate, rather than abolish, Nell2 activity, and would have to be tested for effects on cognition, mood, and seizure susceptibility over long periods.
From a clinical perspective, the most promising application of this research may be in risk staging and early intervention. If Nell2-related hyperexcitability proves measurable in humans-whether through imaging signatures, cerebrospinal fluid markers, or blood-based proxies-it could help identify APOE4 carriers whose circuits are already under strain but who remain cognitively normal. Those individuals might benefit most from lifestyle changes, existing anti-seizure medications being tested in Alzheimer’s, or future Nell2-targeted drugs.
Designing such trials will not be simple. Enrolling symptom-free middle-aged adults and following them for years to detect subtle cognitive changes is expensive and slow. Regulators will also demand strong evidence that any intervention targeting Nell2 affects meaningful clinical outcomes, not just biomarker profiles. That raises the bar for preclinical work: researchers will need to show that correcting Nell2-driven hyperexcitability in animals delays or prevents memory decline, not merely normalizes electrophysiological readouts.
What Nell2 means for how we think about Alzheimer’s risk
Despite the open questions, the Nell2 story nudges the field further away from a plaque-centric view of Alzheimer’s and toward a circuit-based model of risk. In this view, APOE4 sets up a long-running imbalance in hippocampal networks, driven in part by proteins like Nell2, that makes the brain more vulnerable to later insults. Amyloid and tau still matter, but they emerge against a backdrop of decades-long electrical stress.
For patients and families, the immediate implications are modest: there is no Nell2 test or therapy available, and standard advice about cardiovascular health, sleep, and cognitive engagement remains unchanged. For scientists and drug developers, however, the work offers a concrete molecular handle on an early, preclinical phase of disease that has been difficult to target. If future studies confirm that Nell2 plays a similar role in human brains, it could become a key node in strategies aimed at preventing Alzheimer’s before memory ever falters.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
